bluebird bio soars on 1st-qtr update

10 May 2024
bluebird_bio_large

US biotech bluebird bio (Nasdaq: BLUE) saw its shares close up almost 15% at $1.12 yesterday, after it reported first quarter 2024 results and business highlights, including recent commercial and operational progress.

Total revenue, net was $18.6 million for the three months, compared to $2.4 million for the like 2023 period. The company’s cash, cash equivalents and restricted cash balance was around $264 million, including restricted cash of about $52 million, as of March 31, 2024

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biotechnology